Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm Phase 2 Study of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 Risk Myelodysplastic Syndrome
2013-000672-15Phase 2Completed
- Sponsor
- Onconova Therapeutics, Inc.
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rigosertib in myelodysplastic syndrome (MDS), sponsored by Onconova Therapeutics, Inc. Primary endpoint: Onset of hematological improvement. Started Apr 2013; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2013-000672-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000672-15.